Structure-activity relationships of heparin-mimicking compounds in induction of bFGF release from extracellular matrix and inhibition of smooth muscle cell proliferation and heparanase activity.
A series of nine synthetic polyaromatic compounds were synthesized by polymerization of aromatic ring monomers with formaldehyde, which yield substantially ordered backbones with different functional anionic groups (hydroxyl and carboxyl) on the phenol ring. These compounds were tested for their heparin-mimicking activity: (1) inhibition of heparanase activity; (2) inhibition of SMC proliferation; and (3) release of bFGF from the ECM. We demonstrate that compounds that have two hydroxyl groups para and ortho to the carboxylic group and a carboxylic group at a distance of two carbons from the phenol ring inhibit heparanase activity and SMC proliferation, as well as induced an almost complete release of bFGF from ECM. Addition of a methyl group next to the carboxylic group led to a preferential inhibition of heparanase activity. Similar results were obtained with a compound that contains one hydroxyl group para to the carboxylic group and an ether group near the carboxylic group on the phenol ring. Preferential inhibition of SMC proliferation was best achieved when the position of the hydroxyl group is para and ortho to the carboxylic group and the carboxylic group is at a distance of one carbon from the phenol ring. On the other hand, for maximal release of bFGF from ECM, the position of the carboxylic group should be three carbons away from the phenol ring. These new heparin-mimicking compounds may have a potential use in inhibition of tumor metastasis, arteriosclerosis, and inflammation.
Department of Oncology, Hadassah-Hebrew University Hospital, Jerusalem, Israel. Miriam.Benezra@MSSM.edu
Miriam
M
Benezra
Rivka
R
Ishai-Michaeli
Shmuel A
SA
Ben-Sasson
Israel
I
Vlodavsky
D000818:Animals; D002417:Cattle; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D005109:Extracellular Matrix / Q000187:drug effects; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism* / Q000494:pharmacology; D005966:Glucuronidase / Q000378:metabolism; D006493:Heparin / Q000737:chemistry* / Q000494:pharmacology*; D006497:Heparan Sulfate / Q000378:metabolism; D006841:Hydrocarbons, Aromatic / Q000737:chemistry / Q000494:pharmacology; D018716:Molecular Mimicry; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects* / Q000502:physiology*; D013329:Structure-Activity Relationship; D013917:Thrombin / Q000494:pharmacology; D000099175:Heparanase
D016222:Fibroblast Growth Factor 2; D005966:Glucuronidase; D006493:Heparin; D006497:Heparan Sulfate; D006841:Hydrocarbons, Aromatic; D013917:Thrombin; D000099175:Heparanase